Silver Book Fact

Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.

Lasker Foundation. Exceptional Returns: The economic value of America’s investment in medical research. 2000; https://www.medscape.com/viewarticle/447944

Reference

Title
Exceptional Returns: The economic value of America’s investment in medical research
Publisher
Funding First
Publication Date
2000
Authors
Lasker Foundation
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • 30 drugs are currently in development for osteoporosis.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.